Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT03423199

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY (PATHWAY)

Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Sponsor: Korean Cancer Study Group

Conditions Breast Neoplasms

Interventions Goserelin Palbociclib Placebo Tamoxifen

Updated 16 times since 2018 Last updated: Mar 20, 2024 Started: Feb 9, 2018 Primary completion: Sep 30, 2025 Completion: Sep 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Breast Neoplasms, this trial is ongoing. The trial is conducted by Korean Cancer Study Group and has accumulated 16 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

16 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Apr 2023 — Apr 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 11 earlier versions

May 2022 — Apr 2023 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — May 2022 [monthly]

Active Not Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Oct 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE3
Jul 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE3
Jul 2019 — Jul 2020 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Dec 2018 — Jul 2019 [monthly]

Recruiting PHASE3
Aug 2018 — Dec 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Mar 2018 — May 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korean Cancer Study Group
National Cancer Center, Japan
Pfizer

Data source: National Cancer Center, Japan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akashi, Japan , Chiba, Japan , Fukuoka, Japan , Gyeonggi-do, South Korea , Kashiwa, Japan , Matsuyama, Japan , Minato-Ku, Japan , Nagoya, Japan , Osaka, Japan , Sapporo, Japan and 7 more locations